Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Cytarabine CNS Prophylaxis in Adult ALL
NCT02043587Phase 2Terminated
- Sponsor
- University of California, San Diego
- Start
- Jan 2014
- Primary completion
- Apr 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liposomal cytarabine in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by University of California, San Diego. Primary endpoint: Event-free survival at 3 years. Started Jan 2014; status: terminated.
02
Drugs
liposomal cytarabine
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT02043587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02043587.